Search
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Mixtures: FOLISTER COMPLEX HAIR LOTION (R), FOLISTER COMPLEX HAIR LOTION (R)Synonyms: Clobetasol propionate EEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalIn addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will … By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.
Grazoprevir
go.drugbank.com/drugs/DB11575Approvedin combination with [DB11574] for genotypes 1a, 1b, and 4 of Hepatitis C [A19593]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy
Motexafin gadolinium
go.drugbank.com/drugs/DB05428InvestigationalMotexafin gadolinium is studied in the treatment of cancer by Pharmacyclics.
Categories: Compounds used in a research, industrial, or household settingSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Chloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedA hypnotic and sedative used in the treatment of insomnia. … The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Pegargiminase
go.drugbank.com/drugs/DB06592InvestigationalPegargiminase is an anticancer agent.
Categories: Compounds used in a research, industrial, or household settingPlasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.